$BKYI

BIO-key (BKYI) reported Q2 2026 revenue of $1.92M, up 13% YoY, with license fees growing 53%. Net loss improved 51% to $577K. Gross margin rose to 87% due to high-margin license fees. The company raised $2.5M from warrants and reduced debt by $350K. Management expects revenue growth and profitability in H2 2026, driven by international expansion and AI security initiatives.

BIO KEY INTERNATIONAL INC (BKYI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BIO-key’s Bottom Line Improves 51% on 13% Rise in Q2 Revenues Reflecting Strength with Government, Defense, and Financial Sector Customers Globally; Call Tomorrow at 10am ET Holmdel, NJ – August 13, 2026 – BIO-key ® International, Inc. (Nasdaq: BKYI), a global leader

BIO KEY INTERNATIONAL INC (BKYI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 10, 2026, BIO-key International, Inc. (the “Company”) entered into a warrant exercise agreement (the “Warrant Exercise Agreement”) with an existing institutional investor (the “Investor”) to exercise certain outstand

BIO-key International (Nasdaq: BKYI) said it, with partner Visualforma, won a new contract to strengthen digital identity security for a Portuguese national security agency. The deployment includes PortalGuard (MFA, SSO, identity governance), WEB-key biometrics, Identity-Bound Biometrics, PIN:You, and EcoID III scanners, aiming to improve access assurance and compliance.

BIO-key International (Nasdaq: BKYI) said it, with partner Visualforma, won a contract to strengthen digital identity security for a Portuguese national security agency. The deployment expands their public-sector collaboration and includes PortalGuard, WEB-key, Identity-Bound Biometrics, PIN:You, and EcoID III scanners, aiming to improve authentication, privileged access protection, and compliance.

BIO-key International (Nasdaq: BKYI) said it partnered with Maktabi Tech to deploy BIO-key’s PortalGuard IAM platform for identity security in schools and universities across Saudi Arabia, Jordan, and the UAE. The platform includes MFA, SSO, passwordless authentication, and Identity-Bound Biometrics, supporting Vision 2030 digital transformation, according to the companies.

BIO-key International (Nasdaq: BKYI) said the Central Bank of Jordan is working with it on a national initiative to modernize end-client authentication across Jordan’s financial sector. The goal is to move to biometric-first authentication and reduce reliance on passwords and tokens. BIO-key will use PortalGuard and WEB-key, with scope and timeline to be developed.

BIO-key International (Nasdaq: BKYI) said Nasdaq notified it that trading of its common stock will resume on July 8, 2026. The company regained compliance after a June 16 Nasdaq Hearings Panel found it met continued listing standards, including minimum bid price and SEC filing requirements. It will be monitored for one year under Nasdaq Rule 5815(d)(4)(B) until July 6, 2027.

BIO-key International (NASDAQ: BKYI), a biometric identity and authentication provider, will host its Q1 2026 investor call and webcast on Monday, May 18th, at 10 a.m. ET. Chairman & CEO Mike DePasquale and CFO Cecilia Welch will lead the presentation and Q&A. The event will include phone dial-in, a live webcast, and a three-month replay for investors.

BIO-key International, Inc. (BKYI) has secured a multi-year partnership with Mozambique's national electronic payments network, SIMO, to enhance identity and access security. This collaboration with regional integrator RunLevel integrates BIO-key's PortalGuard IAM platform and PIN:You tokenless authentication into SIMO's operations, marking BIO-key's 11th customer in the global banking sector. Despite this strategic win, BIO-key faces financial challenges including declining revenue growth and an Altman Z-Score indicating potential financial distress, though insider ownership remains high.